OTHER FUNCTIONS CIRCULATING TUMOR CELL ENUMERATION PRODUCT

Award Information
Agency:
Department of Health and Human Services
Branch:
N/A
Amount:
$999,613.00
Award Year:
2012
Program:
SBIR
Phase:
Phase II
Contract:
N44CO120049
Agency Tracking Number:
N44CO120049
Solicitation Year:
2012
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
EPIC SCIENCES, INC.
EPIC SCIENCES, INC., SAN DIEGO, CA, 92121-1140
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
829863294
Principal Investigator
 DAVID NELSON
 (858) 356-6611
 DAVID@EPICSCIENCES.COM
Business Contact
 DAVID NELSON
Phone: (858) 356-6611
Email: DAVID@EPICSCIENCES.COM
Research Institution
 Stub
Abstract
This SBIR Phase II controct application is submitted in response to the invitation that was extended after successful completion of the phase I entitled 'Circulating Tumor Cell Enumeration Product'. The Phase /I will demonstrate dinical utility of the product as a surrogate for tissue confirmation of suspected primary lung cancer. The phase I contract was awarded in response to the 2009 solicitation topic 272 and is aimed at developing a clinically useful method for the identification and enumeration of Circulating tumor cells suitable for early stage commercialization and Implementation as a point of care solution. Point of Care in this context is defined as an easily deployable technology with low cost of consumables and devices that is scalable to an eventual point of care implementation. The ultimate goal of getting the test as close as possible to the patient is a key driver in the assay development. It was in pursuit of this goal that the methodology for CTC enumeration was restricted to a method that maintained the ability for downstream characterization. During the phase I contract period, we have developed and both technically and dinically validated molecular characterization of identified CTCs, which can be applied after the initial identification and enumeration is completed. This provides a solid product foundation of the initial product as a fluid biopsy that identifies meaningful numbers of disease derived cells in the majority of patients. The phase II will focus on the two applicable and expected activities, the first being the development of a GLP validated assay and second being the testing of sufficient number of patient samples to demonstrate clinical utility.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government